Key result
Standardized liberation trials are linked to ~88% faster successful VV ECMO liberation.
Why the study?
There is a paucity of evidence around strategies to liberate patients from venovenous ECMO for acute respiratory failure.
Do standardized liberation trials reduce the duration of venovenous ECMO in patients with acute respiratory failure?
Cohort (n=262)
No
Do standardized liberation trials reduce the duration of venovenous ECMO in patients with acute respiratory failure?
Hazard Ratio: 1.88 (95% CI 1.16–3.06)
p-value: p=0.01
Implementing standardized liberation trials for patients on VV ECMO for severe respiratory failure is associated with reduced ECMO duration without increasing unsafe liberation.
Standardized liberation trials may shorten VV ECMO duration; leaves open prospective confirmation of safety and mortality impact.
Rationale There is a paucity of evidence around strategies to liberate patients from venovenous (VV) extracorporeal membrane oxygenation (ECMO) for acute respiratory failure. Objectives The primary aim of this study was to determine if adopting standardized liberation trials (SLTs) for VV ECMO is associated with the duration of ECMO. The secondary aim was to identify factors associated with unsafe liberation and the effects of unsafe liberation on mortality to intensive care unit (ICU) discharge. Methods This was a single-center retrospective cohort study of patients on VV ECMO for severe respiratory failure comparing endpoints between intervention (SLT) and control (no SLT) periods. Results A total of 262 patients were included in the study, 13% (35 of 262) received SLTs, and 150 patients were decannulated from ECMO. Implementing SLTs was strongly associated with the duration of VV ECMO to first successful liberation trial (hazard ratio [HR], 1.88 [95% confidence interval (CI), 1.16 to 3.06]; P = 0.01) and decannulation (HR, 1.92 [95% CI, 1.0 to 3.06]; P = 0.01) without increasing the frequency of unsafe liberation (21% [5 of 23] with SLTs vs. 19% [24 of 127] without SLTs; odds ratio [OR], 1.19 [95% CI, −0.4 to 3.5]; P = 0.7). Unsafe liberation was strongly associated with ICU mortality (HR, 4.15 [95% CI, 1.24 to 13.9]; P = 0.02). Factors associated with unsafe liberation were respiratory rate (OR, 1.49 per 5 breaths/min increase [95% CI, 1.07 to 2.08]; P = 0.02) and ratio of partial pressure of arterial oxygen to fraction of inspired oxygen (OR, 0.73 per 30 mm Hg increase [95% CI, 0.57 to 0.93]; P = 0.01) immediately before decannulation. Conclusions Incorporating SLTs was significantly associated with the duration of VV ECMO, without increasing the frequency of unsafe liberation. Unsafe liberation was associated with increased ICU mortality.
No takes yet. Share an insight, caveat, or question.
Teijeiro‐Paradis et al. (2025) conducted a cohort in Severe respiratory failure (n=262). Standardized liberation trials (SLTs) vs. No SLTs was evaluated on Duration of VV ECMO to first successful liberation trial (HR 1.88, 95% CI 1.16 to 3.06, p=0.01). Implementing standardized liberation trials for patients on VV ECMO was associated with the duration to first successful liberation trial (HR 1.88; 95% CI 1.16-3.06; P=0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: